Title: Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA
clearance in chronic hepatitis b patients
Version: 2 Date: 19 Nov 2024
Reviewer:  Panagiotis Tsibouris
Reviewer's report:
The title seems incoherent Abstract Numerical values should be provided apart from the p-values
All abbreviations should be explained in their first appearance in the text Abstract results are a
bit confusing concerning time point of various measurements Methods Why had 100 IU and not
2000IU limit selected? Which antibiotic have been used as anti-infective treatment What were
the limits for PT, APTT or Fib accepted? In what way was fibrosis evaluated? Has liver biopsy
been performed or transient elastography? Immunodeficiency should be also defined Were all
patients with other liver diseases apart from chronic hepatitis B excluded? What about HDV
co-infection? In what extent was MASLD accepted? What quantity of alcohol was accepted?
Description of the study population belongs in the results The time-points of liver function
evaluation should be defined Statistics Power of the study should be calculated Multi-variated
analysis is advisable Results Side effects should be graded
Title: Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA
clearance in chronic hepatitis b patients
Version: 2 Date: 19 Nov 2024
Reviewer:  Panagiotis Tsibouris
Reviewer's report:
The title seems incoherent Abstract Numerical values should be provided apart from the p-values
All abbreviations should be explained in their first appearance in the text Abstract results are a
bit confusing concerning time point of various measurements Methods Why had 100 IU and not
2000IU limit selected? Which antibiotic have been used as anti-infective treatment What were
the limits for PT, APTT or Fib accepted? In what way was fibrosis evaluated? Has liver biopsy
been performed or transient elastography? Immunodeficiency should be also defined Were all
patients with other liver diseases apart from chronic hepatitis B excluded? What about HDV
co-infection? In what extent was MASLD accepted? What quantity of alcohol was accepted?
Description of the study population belongs in the results The time-points of liver function
evaluation should be defined Statistics Power of the study should be calculated Multi-variated
analysis is advisable Results Side effects should be graded
Please review this paper.
user
Title: Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA
clearance in chronic hepatitis b patients
Version: 2 Date: 19 Nov 2024
Reviewer:  Panagiotis Tsibouris
Reviewer's report:
The title seems incoherent Abstract Numerical values should be provided apart from the p-values
All abbreviations should be explained in their first appearance in the text Abstract results are a
bit confusing concerning time point of various measurements Methods Why had 100 IU and not
2000IU limit selected? Which antibiotic have been used as anti-infective treatment What were
the limits for PT, APTT or Fib accepted? In what way was fibrosis evaluated? Has liver biopsy
been performed or transient elastography? Immunodeficiency should be also defined Were all
patients with other liver diseases apart from chronic hepatitis B excluded? What about HDV
co-infection? In what extent was MASLD accepted? What quantity of alcohol was accepted?
Description of the study population belongs in the results The time-points of liver function
evaluation should be defined Statistics Power of the study should be calculated Multi-variated
analysis is advisable Results Side effects should be graded
assistant